Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, and Pharmacokinetics Phase ⅠStudy of a Selective 5-ht6 Receptor Antagonist, HEC30654AcOH, Following Single and Multiple Ascending Doses Single-center, Randomized, Double-blind in Healthy Subjects

Next Previous
Trial Profile

Safety, Tolerability, and Pharmacokinetics Phase ⅠStudy of a Selective 5-ht6 Receptor Antagonist, HEC30654AcOH, Following Single and Multiple Ascending Doses Single-center, Randomized, Double-blind in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HEC30654-AcOH (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Sunshine Lake Pharma

Most Recent Events

  • 01 May 2026 Status changed from recruiting to completed.
  • 02 Apr 2019 Planned End Date changed from 23 Apr 2019 to 30 Nov 2019.
  • 02 Apr 2019 Planned primary completion date changed from 23 Feb 2018 to 30 Oct 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top